Generali Investments CEE investicni spolecnost a.s. Takes $450,000 Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Generali Investments CEE investicni spolecnost a.s. acquired a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 20,400 shares of the company's stock, valued at approximately $450,000.

A number of other institutional investors also recently added to or reduced their stakes in the business. Smithfield Trust Co boosted its stake in shares of Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock worth $50,000 after acquiring an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $50,000. Venturi Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $60,000. Ameliora Wealth Management Ltd. acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $66,000. Finally, Farther Finance Advisors LLC raised its position in shares of Teva Pharmaceutical Industries by 273.5% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,538 shares of the company's stock worth $82,000 after purchasing an additional 3,323 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Trading Down 0.1 %

Shares of NYSE TEVA traded down $0.01 during trading on Friday, hitting $15.34. 11,322,175 shares of the company traded hands, compared to its average volume of 12,799,828. Teva Pharmaceutical Industries Limited has a 1 year low of $12.51 and a 1 year high of $22.80. The company has a 50-day moving average price of $18.85 and a 200-day moving average price of $18.38. The firm has a market capitalization of $17.40 billion, a P/E ratio of -10.58, a P/E/G ratio of 1.44 and a beta of 0.82. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97.

Remove Ads

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, equities analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Insider Activity

In related news, Director Roberto Mignone sold 286,000 shares of the company's stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares of the company's stock, valued at approximately $15,296,950. This represents a 29.15 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.55% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on TEVA. UBS Group cut their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. StockNews.com downgraded Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Friday. Piper Sandler boosted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, January 17th. Bank of America cut their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a report on Thursday. Finally, Barclays cut their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of "Moderate Buy" and a consensus target price of $23.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.